泽立美大幅降价，儿童湿疹用药进入无激素时代

Core Points - Shanghai Zedman Pharmaceutical Technology Co., Ltd. announced a significant price reduction for its innovative drug, Zeli Mei® (Bimekizumab cream), from 980 yuan to 360 yuan, a decrease of 63%, effective from July 21, 2025 [1] - Zeli Mei is the world's first non-hormonal drug targeting AhR for the treatment of atopic dermatitis, suitable for both children and adults with mild to moderate conditions [1] - The drug was approved for market launch in November 2024 through a priority review process by the National Medical Products Administration, addressing a major gap in pediatric eczema treatment [1] Clinical Value - Professor Zhang Jianzhong from Peking University People's Hospital summarized the clinical value of Zeli Mei cream as: filling the gap for non-hormonal external treatment for children over 2 years old, excellent efficacy with an EASI75 response rate of 83.9% in children, and long-term safe use due to localized application without systemic exposure [2] - The company stated that the price adjustment is a result of optimized production efficiency and cost reduction, aiming to make the innovative therapy more accessible to eczema patients [2] Market Presence - Zeli Mei cream is currently available for sale on online platforms such as JD Health and Alibaba Health, as well as in select offline pharmacies [2] - The company plans to further expand its sales channels to benefit more patient families [2]